Managing gout in primary care
Part 1 - Talking about gout: time for a re-think

Gout is a treatable form of arthritis that is associated with...

Managing gout in primary care
Part 2 -  Controlling gout with long-term urate-lowering treatment

Urate-lowering medicines should be considered and discussed...

Biosimilars: the future of prescribing biological medicines

Biological medicines are an important advancement in the pharmaceutical...

Celecoxib: the “need to know” for safe prescribing

Celecoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor...

Managing pain in osteoarthritis: focus on the person

The progression of osteoarthritis varies from person to person....

Diagnosis and management of axial spondyloarthritis in primary care

Ankylosing spondylitis is a relatively uncommon inflammatory...

Biosimilars: what does a primary care clinician need to know?

Biosimilars - what does a primary care clinician need to know?

”Biosimilars” is likely to become an increasingly familiar term...

The New Zealand Laboratory Schedule and Test Guidelines: genetic tests

The New Zealand Laboratory Schedule provides clinicians with...

Safer prescribing of high-risk medicines - Methotrexate: potentially fatal in overdose

Low-dose methotrexate is commonly used in the treatment of patients...

Investigating myalgia in patients taking statins

Muscle pain (myalgia) and weakness is experienced by up to 10%...

Gout update: Febuxostat now subsidised on Special Authority

This article has been archived. If you would like access...

A conversation about gout…

In New Zealand, the majority of people with gout have higher...

Measuring serum urate levels

Gout is a common form of inflammatory arthritis that is caused...

Biologic medicines for the treatment of inflammatory conditions: What does primary care need to know?

Patients with severe immune-mediated inflammatory diseases,...

Non-steroidal anti-inflammatory drugs (NSAIDs): Making safer treatment choices

Non-steroidal anti-inflammatory drugs (NSAIDs) are successfully...

Calcium pyrophosphate deposition disease: The arthropathy formerly known as “Pseudogout”

A number of clinical syndromes are associated with the precipitation...

Giant cell arteritis: Always keep it in your head

Giant cell arteritis, also referred to as temporal arteritis,...

Polymyalgia rheumatica: Look before you leap

Polymyalgia rheumatica is an inflammatory condition that causes...

An update on the management of gout

This article has been archived. If you would like access...

The medical management of gout revisited

Gout has a significant impact on Māori in New Zealand. Management...

Gout: an alarm bell for diabetes and cardiovascular disease

Counties Manukau DHB Māori Gout Action Group have identified...

Genes, fructose, allopurinol and gout

A short article on gout with specific reference to Pacific...

TNF inhibitors - an update

Tumour necrosis factor (TNF) inhibitors are used in the treatment...

Prevention of osteoporosis

Osteoporosis and subsequent fracture may be prevented by maintaining...

Symptomatic management of osteoarthritis

The key treatment of osteoarthritis is to provide information...

Rheumatoid arthritis - monitoring of DMARDs

Most people with rheumatoid arthritis require early treatment...

Update: Gout in the Māori community

Gout is a significant health issue for Māori. This article...

Gout - Hit the target

Gout is an arthritis caused by the inflammatory response to...

Dear Dave

What is the significance of the warning between ACE inhibitors...